Pulmonary Inflammatory Response in Lethal COVID-19 Reveals Potential Therapeutic Targets and Drugs in Phases III/IV Clinical Trials

• मुख्य लेखकों: Andrés López-Cortés (लेखक), Santiago Guerrero (लेखक), Esteban Ortiz-Prado (लेखक), Verónica Yumiceba (लेखक), Antonella Vera-Guapi (लेखक), Ángela León Cáceres (लेखक), Katherine Simbaña-Rivera (लेखक), Ana María Gómez-Jaramillo (लेखक), Gabriela Echeverría-Garcés (लेखक), Jennyfer M. García-Cárdenas (लेखक), Patricia Guevara-Ramírez (लेखक), Alejandro Cabrera-Andrade (लेखक), Lourdes Puig San Andrés (लेखक), Doménica Cevallos-Robalino (लेखक), Jhommara Bautista (लेखक), Isaac Armendáriz-Castillo (लेखक), Andy Pérez-Villa (लेखक), Andrea Abad-Sojos (लेखक), María José Ramos-Medina (लेखक), Ariana León-Sosa (लेखक), Estefanía Abarca (लेखक), Álvaro A. Pérez-Meza (लेखक), Karol Nieto-Jaramillo (लेखक), Andrea V. Jácome (लेखक), Andrea Morillo (लेखक), Fernanda Arias-Erazo (लेखक), Luis Fuenmayor-González (लेखक), Luis Abel Quiñones (लेखक), Nikolaos C. Kyriakidis (लेखक)
• स्वरूप: पुस्तक
• प्रकाशित: Frontiers Media S.A., 2022-03-01T00:00:00Z.
• विषय: article
• ऑनलाइन पहुंच: Connect to this object online.

Background: It is imperative to identify drugs that allow treating symptoms of severe COVID-19. Respiratory failure is the main cause of death in severe COVID-19 patients, and the host inflammatory response at the lungs remains poorly understood.Methods: Therefore, we retrieved data from post-mortem...